| Literature DB >> 32304704 |
Maya Farah1, Alexandre Reuben2, Ivelina Spassova3, Richard K Yang1, Linda Kubat3, Priyadharsini Nagarajan1, Jing Ning4, Wen Li4, Phyu P Aung1, Jonathan L Curry5, Carlos A Torres-Cabala6, Courtney W Hudgens7, Selma Ugurel8, Dirk Schadendorf8, Curtis Gumbs9, Latasha D Little9, Andrew Futreal9, Ignacio I Wistuba7, Victor G Prieto6, Linghua Wang9, Michael K Wong10, Jennifer A Wargo11, Jürgen C Becker12, Michael T Tetzlaff13.
Abstract
The integrity of the immune system represents a pivotal risk factor and prognostic biomarker for Merkel cell carcinoma. A higher density of tumor-associated T cells correlates with improved Merkel cell carcinoma-specific survival, but the prognostic importance of the T-cell infiltrate reactivity is unknown. We evaluated the T-cell receptor repertoire associated with 72 primary Merkel cell carcinomas and correlated metrics of the T-cell receptor repertoire with clinicopathologic characteristics and patient outcomes. We showed that a high Simpson's Dominance index (SDom) was significantly associated with fewer metastases (P = 0.01), lower stage at presentation (P = 0.02), lower final stage at last follow-up (P = 0.05), and longer time to first lymph node metastasis (P = 0.04). These correlations were mostly preserved in the Merkel cell polyomavirus-negative subgroup. Combining SDom with CD3+ or CD8+ T-cell density revealed three distinct prognostic groups with respect to disease-specific survival. Patients with both high SDom and high CD3+ or CD8+ T-cell density had markedly improved disease-specific survival compared with patients with low SDom and low CD3+ or CD8+ T-cell density (P = 0.002 and P = 0.03, respectively). Patients with either high SDom or high CD3+ or CD8+ had intermediate disease-specific survival. Our findings demonstrate that the quality of the tumor-associated T-cell infiltrate informs patient prognosis in primary Merkel cell carcinoma beyond the T-cell density.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32304704 DOI: 10.1016/j.jid.2020.02.031
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551